Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation
Authors:
- 26 July 2004
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 34 (6) , 515-519
Abstract
Mast cell leukemia (MCL) is a rare form of aggressive mastocytosis with a reported median survival below 6 months. Casuistic reports suggest the effectiveness of allogeneic bone marrow transplantation (BMT) for MCL. However, these reports lack clear evidence for a graft-versus-mast-cell (GvMC) effect. We prospectively investigated the GvMC at different time points after allogeneic BMT and donor-lymphocyte infusions (DLI). Samples were gathered from a patient with MCL treated with allogeneic BMT from an unrelated HLA identical donor. Parameters for detection of a GvMC effect included flow cytometrical analysis of mast cell (MC) populations in peripheral blood and BM, BM smear and histology, chimerism analysis of flow cytometrically sorted BM CD117+/CD34- MC and testing for anti-mast cell reactivity of donor lymphocytes by interferon (IFN)- ELISPOT. DLIs reduced MC from 5 to 0.5%. MC chimerism analysis demonstrated a complete recipient genotype after BMT, suggesting that the persistent mastocytosis was part of residual neoplastic disease. At 3.7 years after BMT, there is some evidence for relapse. In summary, BMT and DLIs attenuated the mastocytosis from an aggressive to an indolent form and may have improved the patients' prognosis. The in vitro data of our study indicate for the first time the existence of a GvMC effect.Keywords
This publication has 10 references indexed in Scilit:
- Imatinib for systemic mast-cell diseaseThe Lancet, 2003
- Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit geneBlood, 2002
- The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutationsBlood, 2002
- Diagnostic criteria and classification of mastocytosis: a consensus proposalLeukemia Research, 2001
- Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34+, c-kit+, and Expresses Aminopeptidase N (CD13)Blood, 1999
- Expression of Bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemiaAmerican Journal of Hematology, 1999
- A new c‐kit mutation in a case of aggressive mast cell diseaseBritish Journal of Haematology, 1997
- Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantationBlood, 1994
- Malignant mastocytosis with circulating mast cellsAmerican Journal of Hematology, 1990
- Mast Cell Leukemia: Report of a Case and Review of the LiteratureMayo Clinic Proceedings, 1986